Capacity challenges

PRODUCTION AREA OVERVIEW
• (1) Reactors (SS, GL, Hastelloy): 3.4 – 16 m3 • (2) Centrifuges (Hastelloy): 1,600 mm diameter • (2) Conical Dryers(Hastelloy): 3 m3 Other process steps:  Distillation, Filtration, Sieving & Milling
...

Commercial Cell Culture Suite w/Primary capture              Total area 650 m2

·        Small scale cultivation grade C, large scale and primary capture grade D

...

From pre-clinical development to commercial supply, Patheon by Thermo Fisher Scientific is an industry leader in the development and manufacture of mammalian cell culture drug substances. Patheon offers biotech and pharmaceutical companies the ability to pursue opportunities around the globe with a fully i...

PODs are readily deployable, flexible, prequalified and scalable cleanrooms for any pharmaceutical/biopharmaceutical need. PODs fulfill the demands of industry and regulatory authorities where requirements of containment and segregation are important to protect products and the environment. G-CON’s PODs pr...

G-CON has developed a portfolio of six standard cleanroom PODs. These PODs are fully designed, allowing them to be mass-produced. Delivery time is as little as 3 months with the future goal of being able to maintain an inventory of ready to deliver PODs. Mass production of standard PODs will also lower cos...

 In biomanufacturing the only certainty is risk and the only constant is change. Future proofing any capacity expansion to allow for the unknown product or technology is challenging. Location, personnel, timing, process, and planning are critical success factors. KUBio modular facilities are designed ...